This unique IPF meeting is your opportunity to join the leading minds across biopharma and academia to reduce the expansive translational gap that exists in current IPF drug development.
IPF Summit 2017 brought over 90 of the leading minds across biopharma and academia together to discuss shortening the translational gap that exists in current IPF drug development. Sessions enabled attendees to:
The Idiopathic Pulmonary (IPF) Summit is the only event solely dedicated to transforming discovery & translational fibrosis research into disease modifying IPF therapeutics.
"This conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics!” AstraZeneca - Previous Hanson Wade Life Sciences event attendee